An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels

Novel inhibitors in development for hepatocellular carcinoma

(2010) Marcus Alexander Wörns et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model

(2010) Yu-Xiong Feng et al.   HEPATOLOGY

Safety and Feasibility of Using Sorafenib in Recurrent Hepatocellular Carcinoma after Orthotopic Liver Transplantation

(2010) Richard Kim et al.   ONCOLOGY

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudy

(2009) Zhe Zhang et al.   BMC Medicine

Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives

(2009) Raffaele Addeo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Novel advancements in the management of hepatocellular carcinoma in 2008

(2008) Josep M. Llovet et al.   JOURNAL OF HEPATOLOGY

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway

(2008) W Zhang et al.   LEUKEMIA

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatocellular Carcinoma 2009 and Beyond: from the Surveillance to Molecular Targeted Therapy

(2008) Masatoshi Kudo   ONCOLOGY